Zafgen Inc (NASDAQ:ZFGN) insider Thomas E. Hughes sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, March 7th. The stock was sold at an average price of $10.00, for a total transaction of $50,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Zafgen Inc (ZFGN) traded down $0.35 on Friday, reaching $7.27. 158,347 shares of the company were exchanged, compared to its average volume of 224,302. Zafgen Inc has a one year low of $3.21 and a one year high of $10.00. The company has a market cap of $210.00, a price-to-earnings ratio of -3.81 and a beta of -0.65. The company has a quick ratio of 13.61, a current ratio of 14.39 and a debt-to-equity ratio of 0.26.
Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings data on Tuesday, March 6th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.09. equities analysts predict that Zafgen Inc will post -2.2 EPS for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Two Sigma Investments LP lifted its holdings in Zafgen by 91.1% during the 4th quarter. Two Sigma Investments LP now owns 61,048 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 29,101 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Zafgen by 139.1% during the 4th quarter. Bank of New York Mellon Corp now owns 87,571 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 50,939 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Zafgen by 18.3% during the 4th quarter. Acadian Asset Management LLC now owns 104,014 shares of the biopharmaceutical company’s stock valued at $481,000 after buying an additional 16,072 shares in the last quarter. OxFORD Asset Management LLP raised its holdings in shares of Zafgen by 65.0% in the 3rd quarter. OxFORD Asset Management LLP now owns 171,112 shares of the biopharmaceutical company’s stock valued at $585,000 after purchasing an additional 67,394 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Zafgen by 1,701.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 197,287 shares of the biopharmaceutical company’s stock valued at $692,000 after purchasing an additional 186,336 shares in the last quarter. Institutional investors own 52.52% of the company’s stock.
ZFGN has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Zafgen from a “hold” rating to a “buy” rating and set a $9.00 target price for the company in a report on Wednesday, March 7th. JMP Securities restated an “outperform” rating and issued a $20.00 target price (up previously from $11.00) on shares of Zafgen in a report on Wednesday, March 7th. Finally, ValuEngine upgraded shares of Zafgen from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
COPYRIGHT VIOLATION WARNING: “Zafgen Inc (NASDAQ:ZFGN) Insider Thomas E. Hughes Sells 5,000 Shares” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://ledgergazette.com/2018/03/17/zafgen-inc-zfgn-insider-thomas-e-hughes-sells-5000-shares.html.
Zafgen Company Profile
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.